In our cohort, the majority of patients exhibited active IIH, especially in the UCWM group with significantly shorter disease duration, with slightly higher yet not significant change in the pRNFL thickness in this group
Evidence from animal studies, nonhuman primate work, and limited early human data suggests that these medications may reduce alcohol consumption, drug cravings, relapse behaviors, and dopamine-driven reward responses
Indeed, reports that sAC / mice display impairments in both pancreatic insulin secretion and intraperitoneal glucose tolerance (40, 43) support our findings implicating sAC in GLP-1(2836) and/or overall GLP-1 biology
Even patients who discontinued the drug months ago may still have actionable claims
GLP-1 therapy is worth sticking with
[17] [18] The FDA issued a 2023 safety communication advising against probiotic use in preterm infants due to risk of invasive disease